| abstract |
Use of an IL-18 inhibitor for the manufacture of a medicament for the treatment and / or prevention of atherosclerosis, wherein the IL-18 inhibitor is selected from the group consisting of antibodies against IL-18, antibodies against any IL-18 receptor subunit and IL-18 binding protein (IL-18BP), an IL-18BP mutein comprising conservative amino acid substitutions, an IL-18BP fusion protein and heavy chain regions of the immunoglobulin, or the PEGylated IL-18BP, wherein the mutein, the fused protein or the PEGylated IL-18 BP retain the biological activity of binding to IL-18. |